Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Docetaxel
100%
Urothelial Cancer
100%
Advanced or Metastatic
100%
Drug Combination
33%
Gemcitabine
33%
Triplet
33%
Phase I Study
16%
Median Overall Survival
16%
Epirubicin
16%
Doxorubicin
16%
Cisplatin
16%
Previously Untreated Patients
16%
Response Rate
16%
Doublet
16%
Long-term Survival
16%
Anthracyclines
16%
Anti-tumor Response
16%
Transitional Cell Carcinoma
16%
Previously Treated
16%
Patient Response
16%
First-line Regimen
16%
Non-platinum
16%
Chemotherapy-naïve
16%
Renal Impairment
16%
Taxotere
16%
Cisplatin-based Regimen
16%
Transitional Cell Carcinoma of the Urothelium
16%
Gemzar
16%
Platinum-containing Regimens
16%
Medicine and Dentistry
Malignant Neoplasm
100%
Docetaxel
100%
Gemcitabine
42%
Cisplatin
28%
Combination Drug
28%
Epirubicin
28%
Transitional Cell Carcinoma
28%
Platinum
28%
Base
14%
Overall Survival
14%
Doxorubicin
14%
Anthracycline
14%
Chemotherapy
14%
Long Term Survival
14%
Urothelium
14%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Docetaxel
100%
Gemcitabine
42%
Cisplatin
28%
Epirubicin
28%
Combination Drug
28%
Transitional Cell Carcinoma
28%
Platinum
28%
Base
14%
Overall Survival
14%
Doxorubicin
14%
Anthracycline
14%
Long Term Survival
14%
Chemotherapy Regimen
14%
Neuroscience
Docetaxel
100%
Gemcitabine
42%
Cisplatin
28%
Combination Drug
28%
Epirubicin
28%
Doxorubicin
14%
Chemotherapy
14%
Anthracycline
14%
Urothelium
14%